real-world-benefit-shown-in-T2D-treatment
Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
Search
Boehringer Ingelheim half-year results 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Central Nervous System Diseases
Central Nervous System Diseases
DCRI-collaboration-empact-mi
Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
emperor-reduced-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
Anti-fibrotic agent
Anti-fibrotic agent
Promising phase II results in chronic kidney disease
Boehringer Ingelheim’s investigation of novel compound on top of standard of care empagliflozin shows promising results for chronic kidney disease
Survodutide (BI 456906)
BI 456909
Avenciguat (BI 685509)
Avenciguat (BI 685509)
NPY2r agonist
Food intake regulator
European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
BI 765845
Heart disease modulator
CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
FDA-approves-nintedanib-in-SSc-ILD
FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Cardio-Renal-Metabolic Infographic Update 2023
Cardiovascular renal and metabolic diseases infographic
Partnering in Cardio-Renal-Metabolic MAY 2024 CORP .pdf
Annelises story
Listen to Annelise discuss her journey after diagnosis with systemic sclerosis, also known as scleroderma
The liver and its vital connection to our overall health
How health of the liver impacts our interconnected cardiovascular, renal, metabolic system and suffering and can have several comorbidities like obesity.
survodutide top-line results MASH fibrosis
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Phase 3 studies survodutide obesity and overweight
Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Interconnected CRM conditions
Learn about the interconnectivity between the heart, kidney and metabolic systems
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
About Chronic Kidney Disease
CKD is very common and often goes undetected due to its silent nature. Risk factors include high blood pressure and type 2 diabetes.